

# Jordi Dorca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6289651/publications.pdf>

Version: 2024-02-01

108  
papers

6,499  
citations

61984

43  
h-index

66911

78  
g-index

118  
all docs

118  
docs citations

118  
times ranked

5845  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radio-Histological Correlation of Lung Features in Severe COVID-19 Through CT-Scan and Lung Ultrasound Evaluation. <i>Frontiers in Medicine</i> , 2022, 9, 820661.	2.6	4
2	Silicone Stent Versus Fully Covered Metallic Stent in Malignant Central Airway Stenosis. <i>Annals of Thoracic Surgery</i> , 2021, 111, 283-289.	1.3	13
3	Mapping <scp>IPF</scp> helps identify geographic regions at higher risk for disease development and potential triggers. <i>Respirology</i> , 2021, 26, 352-359.	2.3	18
4	Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series. <i>Open Respiratory Archives</i> , 2021, 3, 100080.	0.1	3
5	Comparing Probe-Based Confocal Laser Endomicroscopy With Histology. Are We Looking at the Same Picture?. <i>Archivos De Bronconeumología</i> , 2021, , .	0.8	0
6	Lung Ultrasound Score to Predict Outcomes in COVID-19. <i>Respiratory Care</i> , 2021, 66, 1263-1270.	1.6	12
7	Lung Transplant Improves Survival and Quality of Life Regardless of Telomere Dysfunction. <i>Frontiers in Medicine</i> , 2021, 8, 695919.	2.6	13
8	A prospective study of lung disease in a cohort of early rheumatoid arthritis patients. <i>Scientific Reports</i> , 2020, 10, 15640.	3.3	30
9	Effectiveness of an intensive weight-loss program for severe OSA in patients undergoing CPAP treatment: a randomized controlled trial. <i>Journal of Clinical Sleep Medicine</i> , 2020, 16, 503-514.	2.6	20
10	Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data. <i>Rheumatology International</i> , 2020, 40, 719-726.	3.0	21
11	Infectiousness of patients with smear-negative pulmonary tuberculosis, assessed by Real-time Polymerase Chain Reaction, Xpert <sup>®</sup> MTB/RIF. <i>Journal of Infection</i> , 2020, 80, 298-300.	3.3	1
12	Host- and Pathogen-Related Factors for Acute Cardiac Events in Pneumococcal Pneumonia. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa522.	0.9	5
13	Imbalance in the Expression of Genes Associated with Purinergic Signalling in the Lung and Systemic Arteries of COPD Patients. <i>Scientific Reports</i> , 2019, 9, 2796.	3.3	3
14	Anthropometrical phenotypes are important when explaining obstructive sleep apnea in female bariatric cohorts. <i>Journal of Sleep Research</i> , 2019, 28, e12830.	3.2	14
15	Ultrathin Bronchoscopy with and without Virtual Bronchoscopic Navigation: Influence of Segmentation on Diagnostic Yield. <i>Respiration</i> , 2019, 97, 252-258.	2.6	19
16	Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients. <i>International Journal of COPD</i> , 2018, Volume 13, 141-148.	2.3	9
17	QuantiFERON-TB Gold In-Tube as a Confirmatory Test for Tuberculin Skin Test in Tuberculosis Contact Tracing: A Noninferiority Clinical Trial. <i>Clinical Infectious Diseases</i> , 2018, 66, 396-403.	5.8	18
18	Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. <i>BMC Pulmonary Medicine</i> , 2018, 18, 63.	2.0	59

#	ARTICLE	IF	CITATIONS
19	Defining the role of neutrophil-to-lymphocyte ratio in COPD: a systematic literature review. <i>International Journal of COPD</i> , 2018, Volume 13, 3651-3662.	2.3	38
20	Positive Airway Pressure to Enhance Computed Tomography Imaging for Airway Segmentation for Virtual Bronchoscopic Navigation. <i>Respiration</i> , 2018, 96, 525-534.	2.6	5
21	Is the purinergic pathway involved in the pathology of COPD? Decreased lung CD39 expression at initial stages of COPD. <i>Respiratory Research</i> , 2018, 19, 103.	3.6	9
22	Consenso multidisciplinar sobre prevención y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico. Adaptación al paciente dermatológico. <i>Actas Dermo-sifiliográficas</i> , 2018, 109, 584-601.	0.4	2
23	Addition of hyaluronic acid improves tolerance to 7% hypertonic saline solution in bronchiectasis patients. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661878738.	2.6	11
24	Pulmonary Infections with Nontuberculous Mycobacteria, Catalonia, Spain, 1994-2014. <i>Emerging Infectious Diseases</i> , 2018, 24, 1091-1094.	4.3	28
25	Inflammatory markers and circulating extracellular matrix proteins in patients with chronic obstructive pulmonary disease and left ventricular diastolic dysfunction. <i>Clinical Respiratory Journal</i> , 2017, 11, 859-866.	1.6	10
26	Effectiveness of a Respiratory Day Hospital Program to Reduce Admissions for Exacerbation in Patients with Severe COPD: A Prospective, Multicenter Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 304-310.	1.6	8
27	The microbiome in respiratory medicine: current challenges and future perspectives. <i>European Respiratory Journal</i> , 2017, 49, 1602086.	6.7	194
28	Increasing isolation of rapidly growing mycobacteria in a low-incidence setting of environmental mycobacteria, 1994-2015. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 1425-1432.	2.9	22
29	Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 547-5553.	3.0	44
30	QuantIFERON®-TB Gold In-Tube for contact screening in BCG-vaccinated adults: A longitudinal cohort study. <i>PLoS ONE</i> , 2017, 12, e0183258.	2.5	7
31	Specific IgA against <i>Pseudomonas aeruginosa</i> in severe COPD. <i>International Journal of COPD</i> , 2017, Volume 12, 2807-2811.	2.3	11
32	Vascular disease in COPD: Systemic and pulmonary expression of PARC (Pulmonary and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 Td (A	2.5	6
33	Successful Healing of Tracheal Radionecrosis. <i>Chest</i> , 2016, 150, e147-e150.	0.8	4
34	Factors predicting survival in amyotrophic lateral sclerosis patients on non-invasive ventilation. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 337-342.	1.7	27
35	Declining mortality among hospitalized patients with community-acquired pneumonia. <i>Clinical Microbiology and Infection</i> , 2016, 22, 567.e1-567.e7.	6.0	40
36	Colchicine Treatment for Tracheobronchial Amyloidosis. <i>Respiration</i> , 2016, 91, 251-255.	2.6	12

#	ARTICLE	IF	CITATIONS
37	Aberrant gene methylation and bronchial dysplasia in high risk lung cancer patients. Lung Cancer, 2016, 94, 102-107.	2.0	1
38	Osificación pulmonar dendriforme en un caso subclónico de fibrosis pulmonar familiar. Archivos De Bronconeumología, 2016, 52, e9-e10.	0.8	3
39	Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal, 2016, 48, 1030-1039.	6.7	81
40	Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis. Respiratory Research, 2016, 17, 144.	3.6	40
41	Preclinical lung disease in early rheumatoid arthritis. Chronic Respiratory Disease, 2016, 13, 75-81.	2.4	23
42	Combined Bronchial Artery Embolization and Endobronchial Resection for Bronchial Carcinoid: A Safety and Feasibility Pilot Study. Respiration, 2016, 91, 63-68.	2.6	9
43	Transcutaneous Carbon Dioxide Monitoring in Subjects With Acute Respiratory Failure and Severe Hypercapnia. Respiratory Care, 2016, 61, 428-433.	1.6	13
44	Systemic and Pulmonary Vascular Remodelling in Chronic Obstructive Pulmonary Disease. PLoS ONE, 2016, 11, e0152987.	2.5	20
45	Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices. Respiratory Research, 2015, 16, 82.	3.6	51
46	Transarterial EBUS-TBNA in the Diagnosis of Hilar Lesions. Journal of Bronchology and Interventional Pulmonology, 2015, 22, e19-e22.	1.4	0
47	Personalized Respiratory Medicine: Exploring the Horizon, Addressing the Issues. Summary of a BRN-AJRCCM Workshop Held in Barcelona on June 12, 2014. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 391-401.	5.6	61
48	Gene and Protein Expression of Fibronectin and Tenascin-C in Lung Samples from COPD Patients. Lung, 2015, 193, 335-343.	3.3	4
49	The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. BMJ Open, 2015, 5, e006251-e006251.	1.9	42
50	Roflumilast added to triple therapy in patients with severe COPD: A real life study. Pulmonary Pharmacology and Therapeutics, 2015, 30, 16-21.	2.6	28
51	Impact of an Educational Program to Reduce Healthcare Resources in Community-Acquired Pneumonia: The EDUCAP Randomized Controlled Trial. PLoS ONE, 2015, 10, e0140202.	2.5	10
52	Impact of pre-hospital antibiotic use on community-acquired pneumonia. Clinical Microbiology and Infection, 2014, 20, O531-O537.	6.0	9
53	Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia. Journal of Infection, 2014, 68, 534-541.	3.3	34
54	Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGF $\beta$ 1. BMC Pulmonary Medicine, 2014, 14, 120.	2.0	77

#	ARTICLE	IF	CITATIONS
55	Clinical Features, Etiology and Outcomes of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE, 2014, 9, e105854.	2.5	45
56	Prognostic value of serum albumin levels in hospitalized adults with community-acquired pneumonia. Journal of Infection, 2013, 66, 415-423.	3.3	97
57	Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. Journal of Infection, 2013, 66, 27-33.	3.3	76
58	Infectious etiology of acute exacerbations in severe COPD patients. Journal of Infection, 2013, 67, 516-523.	3.3	45
59	Clinical Features, Etiology, and Outcomes of Community-Acquired Pneumonia in Patients With Diabetes Mellitus. Medicine (United States), 2013, 92, 42-50.	1.0	35
60	Community-Acquired Legionella pneumophila Pneumonia. Medicine (United States), 2013, 92, 51-60.	1.0	102
61	Rainfall Is a Risk Factor for Sporadic Cases of Legionella pneumophila Pneumonia. PLoS ONE, 2013, 8, e61036.	2.5	47
62	High Prevalence of Left Ventricle Diastolic Dysfunction in Severe COPD Associated with A Low Exercise Capacity: A Cross-Sectional Study. PLoS ONE, 2013, 8, e68034.	2.5	51
63	Effect of a 3-Step Critical Pathway to Reduce Duration of Intravenous Antibiotic Therapy and Length of Stay in Community-Acquired Pneumonia. Archives of Internal Medicine, 2012, 172, 922-8.	3.8	108
64	Timing of antibiotic administration and outcomes of hospitalized patients with community-acquired and healthcare-associated pneumonia. Clinical Microbiology and Infection, 2012, 18, 1149-1155.	6.0	30
65	Repeated Aspergillus isolation in respiratory samples from non-immunocompromised patients not selected based on clinical diagnoses: colonisation or infection?. BMC Infectious Diseases, 2012, 12, 295.	2.9	18
66	Obstructive sleep apnoea and metabolic impairment in severe obesity. European Respiratory Journal, 2011, 38, 1089-1097.	6.7	51
67	Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Critical Care, 2011, 15, R96.	5.8	121
68	Community-Acquired Pneumonia in Patients With Liver Cirrhosis. Medicine (United States), 2011, 90, 110-118.	1.0	78
69	Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clinical Microbiology and Infection, 2011, 17, 1659-1665.	6.0	81
70	Tratamiento endoscópico de la fuga aérea persistente alveolo-pleural con una válvula endobronquial unidireccional. Archivos De Bronconeumología, 2011, 47, 371-373.	0.8	14
71	Serotypes and genotypes of Streptococcus pneumoniae causing pneumonia and acute exacerbations in patients with chronic obstructive pulmonary disease. Journal of Antimicrobial Chemotherapy, 2011, 66, 487-493.	3.0	38
72	Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2011, 26, 2899-2906.	0.7	88

#	ARTICLE	IF	CITATIONS
73	Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2010, 29, 1243-1251.	2.9	14
74	Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. <i>Thorax</i> , 2010, 65, 77-81.	5.6	97
75	Long-term relapses after 12-month treatment for <i>Mycobacterium kansasii</i> lung disease. <i>European Respiratory Journal</i> , 2009, 33, 148-152.	6.7	42
76	Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. <i>Respirology</i> , 2009, 14, 105-111.	2.3	62
77	Aetiology of, and risk factors for, recurrent community-acquired pneumonia. <i>Clinical Microbiology and Infection</i> , 2009, 15, 1033-1038.	6.0	58
78	Manejo endovascular de lesión de arteria subclavia izquierda tras toracoplastia por fístula broncopleurales y empiema secundario a <i>Aspergillus fumigatus</i> . <i>Archivos De Bronconeumología</i> , 2008, 44, 338-340.	0.8	2
79	Early mortality in patients with community-acquired pneumonia: causes and risk factors. <i>European Respiratory Journal</i> , 2008, 32, 733-739.	6.7	105
80	Health Care-Associated Pneumonia Requiring Hospital Admission. <i>Archives of Internal Medicine</i> , 2007, 167, 1393.	3.8	285
81	Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2006, 25, 457-462.	2.9	67
82	Clinical Outcomes for Hospitalized Patients with Legionella Pneumonia in the Antigenuria Era: The Influence of Levofloxacin Therapy. <i>Clinical Infectious Diseases</i> , 2005, 40, 794-799.	5.8	129
83	Outpatient Care Compared with Hospitalization for Community-Acquired Pneumonia. <i>Annals of Internal Medicine</i> , 2005, 142, 165.	3.9	211
84	Contribution of a Urinary Antigen Assay (Binax NOW) to the Early Diagnosis of Pneumococcal Pneumonia. <i>Clinical Infectious Diseases</i> , 2004, 38, 222-226.	5.8	182
85	Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations?. <i>Clinical Genetics</i> , 2004, 65, 490-495.	2.0	81
86	Incidence and molecular typing of <i>Mycobacterium kansasii</i> in a defined geographical area in Catalonia, Spain. <i>Epidemiology and Infection</i> , 2004, 132, 425-432.	2.1	24
87	Efficacy and Safety of Sequential Amoxicillin-Clavulanate in the Treatment of Anaerobic Lung Infections. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003, 22, 185-187.	2.9	50
88	Neither questions nor answers, just original data. <i>European Respiratory Journal</i> , 2003, 21, 377.1-377.	6.7	1
89	Molecular Inflammatory Responses Measured in Blood of Patients with Severe Community-Acquired Pneumonia. <i>Vaccine Journal</i> , 2003, 10, 813-820.	3.1	114
90	Title is missing!. <i>Medicine (United States)</i> , 2003, 82, 159-169.	1.0	28

#	ARTICLE	IF	CITATIONS
91	Clinical Diagnosis of Legionella Pneumonia Revisited: Evaluation of the Community-Based Pneumonia Incidence Study Group Scoring System. <i>Clinical Infectious Diseases</i> , 2003, 37, 483-489.	5.8	63
92	Community-Acquired Pneumonia in Very Elderly Patients. <i>Medicine (United States)</i> , 2003, 82, 159-169.	1.0	187
93	Effects of antibiotics on protected specimen brush sampling in ventilator-associated pneumonia. <i>European Respiratory Journal</i> , 2002, 19, 944-951.	6.7	62
94	Etiology, Reasons for Hospitalization, Risk Classes, and Outcomes of Community-Acquired Pneumonia in Patients Hospitalized on the Basis of Conventional Admission Criteria. <i>Clinical Infectious Diseases</i> , 2001, 33, 158-165.	5.8	703
95	Usefulness of Betalactam Therapy for Community-Acquired Pneumonia in the Era of Drug-Resistant <i>Streptococcus pneumoniae</i> : A Randomized Study of Amoxicillin-Clavulanate and Ceftriaxone. <i>Microbial Drug Resistance</i> , 2001, 7, 85-96.	2.0	56
96	Prospective Study of the Usefulness of Sputum Gram Stain in the Initial Approach to Community-Acquired Pneumonia Requiring Hospitalization. <i>Clinical Infectious Diseases</i> , 2000, 31, 869-874.	5.8	199
97	Vertebral and Rib Sarcoidosis: Long-Term Clinical Remission with Methotrexate. <i>Clinical Rheumatology</i> , 1999, 18, 492-494.	2.2	23
98	Usefulness of PCR and Antigen Latex Agglutination Test with Samples Obtained by Transthoracic Needle Aspiration for Diagnosis of Pneumococcal Pneumonia. <i>Journal of Clinical Microbiology</i> , 1999, 37, 709-714.	3.9	50
99	Guidelines for management of adult community-acquired lower respiratory tract infections. <i>European Respiratory Journal</i> , 1998, 11, 986-991.	6.7	196
100	Clinical and Epidemiological Findings in Mechanically-Ventilated Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> Pneumonia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1998, 17, 622-628.	2.9	28
101	Protected bronchoalveolar lavage in the diagnosis of ventilator-associated pneumonia. <i>European Respiratory Journal</i> , 1996, 9, 1500-1507.	6.7	21
102	Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1996, 154, 1456-1461.	5.6	177
103	Efficacy, safety, and therapeutic relevance of transthoracic aspiration with ultrathin needle in nonventilated nosocomial pneumonia.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 1491-1496.	5.6	53
104	Risk factors for nosocomial <i>Legionella pneumophila</i> pneumonia.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1994, 149, 625-629.	5.6	123
105	Fatal lung abscess due to <i>Lactobacillus casei</i> ss <i>rhamnosus</i> .. <i>Thorax</i> , 1992, 47, 992-992.	5.6	1
106	Needle aspiration techniques in the diagnosis of pneumonia.. <i>Thorax</i> , 1991, 46, 601-603.	5.6	21
107	EMPIRICAL TREATMENT OF PNEUMOCOCCAL PNEUMONIA IN SPAIN. <i>Lancet, The</i> , 1989, 333, 1338-1339.	13.7	7
108	Risk Factors and Response to Antibiotic Therapy in Adults with Bacteremic Pneumonia Caused by Penicillin-Resistant <i>Pneumococci</i> . <i>New England Journal of Medicine</i> , 1987, 317, 18-22.	27.0	403